Testing a cell therapy for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a treatment where doctors take immune cells from your tumor, grow more of them in the lab, and put them back into your body to fight the cancer. This approach, called TIL therapy, aims to strengthen your own immune system to target ovarian cancer that has come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ovarian cancer that has returned after previous treatment
- You have at least one tumor (or tumor area) that can be safely removed through biopsy or surgery to collect immune cells
- You do not have a weakened immune system or autoimmune disease that could worsen with this type of therapy
- Your doctor believes you are healthy enough to participate in the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach using your own immune cells (tumor-infiltrating lymphocytes) that have been modified to work better, followed by a combination of oral chemo and immunotherapy. It's for people with ovarian cancer that has come back after standard treatment.
This Phase 1/2 study tests a treatment using tumor-fighting immune cells taken from your cancer (TILs) for certain advanced or metastatic cervical, ovarian, endometrial, or breast cancers. It may help shrink tumors and will track safety, especially in people who have already tried standard treatments.
This trial tests a new therapy made from your own immune cells (called TILs) to fight ovarian cancer. Doctors remove some of your tumor, grow the immune cells in a lab, and then give them back to you to attack the cancer.
This trial tests a personalized cancer vaccine made from your own tumor cells. It is for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after at least one round of platinum chemotherapy.
This trial tests a new type of immune therapy called CAR T-cells (SCT-001) for ovarian cancer that has returned or isn't responding to standard treatments. The cells are engineered to find and attack cancer cells that have a specific marker (TAG-72) on their surface.
This trial tests a treatment made from your own immune cells (TILs) that are taken from a tumor, grown in a lab, and then given back to you to fight cancer. It's for people with solid tumors that have spread or come back after treatment.
Hear when a new Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.